Pfizer CEO says company has already completed its largest deals, no further acquisitions planned

Pfizer chief Albert Bourla addressed investors from the New York Stock Exchange floor, noting that the company has already executed its biggest transactions and has roughly $6 billion earmarked for such activities.

Analysts had been questioning whether Pfizer might pursue additional acquisitions to sustain growth. Bourla reassured the market that there are no plans for further deals at this time.

The comments suggest the company will concentrate on other avenues for expansion, though no specific initiatives were detailed.